{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T09:27:58Z","timestamp":1745314078290},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T00:00:00Z","timestamp":1444694400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s00277-015-2518-5","type":"journal-article","created":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T16:53:05Z","timestamp":1444755185000},"page":"349-350","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib"],"prefix":"10.1007","volume":"95","author":[{"given":"Damien","family":"Luque Paz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Christophe","family":"Ianotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Chauveau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Briac","family":"Guibourg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydie","family":"Lecucq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Lippert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Ugo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,13]]},"reference":[{"issue":"5","key":"2518_CR1","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/sj.leu.2404993","volume":"22","author":"K Hussein","year":"2008","unstructured":"Hussein K, Bock O, Theophile K, Seegers A, Arps H, Basten O et al (2008) Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation. Leukemia 22(5):1059\u201362","journal-title":"Leukemia"},{"issue":"22","key":"2518_CR2","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1182\/blood-2013-07-516385","volume":"122","author":"J Grisouard","year":"2013","unstructured":"Grisouard J, Ojeda-Uribe M, Looser R, Hao-Shen H, Lundberg P, Duek A et al (2013) Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia. Blood 122(22):3694\u20136","journal-title":"Blood"},{"issue":"1","key":"2518_CR3","first-page":"34","volume":"6","author":"I Ursuleac","year":"2013","unstructured":"Ursuleac I, Colita A, Adam T, Jardan C, Ilea A, Coriu D (2013) The concomitant occurrence of JAK2V617F mutation and BCR\/ABL transcript with phenotypic expression\u2014an overlapping myeloproliferative disorder or two distinct diseases?\u2014case report. J Med Life 6(1):34\u20137","journal-title":"J Med Life"},{"issue":"7","key":"2518_CR4","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1182\/blood-2012-11-467787","volume":"121","author":"X Wang","year":"2013","unstructured":"Wang X, Tripodi J, Kremyanskaya M, Blouin A, Roda P, Hoffman R et al (2013) BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia. Blood 121(7):1238\u20139","journal-title":"Blood"},{"issue":"21","key":"2518_CR5","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1200\/JCO.2012.47.8669","volume":"32","author":"O Yamada","year":"2014","unstructured":"Yamada O, Mahfoudhi E, Plo I, Ozaki K, Nakatake M, Akiyama M et al (2014) Emergence of a BCR-ABL translocation in a patient with the JAK2V617F mutation: evidence for secondary acquisition of BCR-ABL in the JAK2V617F clone. J Clin Oncol 32(21):e76\u2013e79","journal-title":"J Clin Oncol"},{"issue":"6","key":"2518_CR6","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.3324\/haematol.2013.102525","volume":"99","author":"A Iurlo","year":"2014","unstructured":"Iurlo A, Gianelli U, Rapezzi D, Cattaneo D, Fermo E, Binda F et al (2014) Imatinib and ruxolitinib association: first experience in two patients. Haematologica 99(6):e76\u2013e77","journal-title":"Haematologica"},{"issue":"25","key":"2518_CR7","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","volume":"122","author":"F Cervantes","year":"2013","unstructured":"Cervantes F, Vannucchi AM, Kiladjian J-J, Al-Ali HK, Sirulnik A, Stalbovskaya V et al (2013) Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 122(25):4047\u201353","journal-title":"Blood"},{"issue":"9","key":"2518_CR8","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799\u2013807","journal-title":"N Engl J Med"},{"issue":"12","key":"2518_CR9","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA et al (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363(12):1117\u201327","journal-title":"N Engl J Med"},{"issue":"5","key":"2518_CR10","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F et al (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372(5):426\u201335","journal-title":"N Engl J Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2518-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-015-2518-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2518-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T09:50:02Z","timestamp":1559037002000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-015-2518-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,13]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["2518"],"URL":"https:\/\/doi.org\/10.1007\/s00277-015-2518-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,13]]}}}